Desmopressin: In adults with nocturia

Drugs

Volumn 65, Issue 1, 2005, Pages 99-107

  Cvetković, Risto S ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; PLACEBO; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ANTIDIURESIS; AREA UNDER THE CURVE; BIOAVAILABILITY; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; HEADACHE; HUMAN; HYPONATREMIA; INFLAMMATION; MULTIPLE SCLEROSIS; NAUSEA; NOCTURIA; NOSE CONGESTION; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SLEEP PATTERN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY EXCRETION; WATER INTOXICATION;

ADULT; DEAMINO ARGININE VASOPRESSIN; HUMANS; URINATION DISORDERS;

EID: 12444324655     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565010-00008     Document Type: Review

References (56)

1. Samuelsson E, Victor A, Tibblin G. A population study of urinary incontinence and nocturia among women aged 20-59 years. Acta Obstet Gynecol Scand 1997; 76: 74-80
2. Jackson S. Lower urinary tract symptoms and nocturia in men and women: prevalence, aetiology and diagnosis. BJU Interanational 1999; 84 Suppl. 1: 5-8
3. van Dijk L, Kooij DG, Schellevis FG. Nocturia in the Dutch adult population. BJU Int 2002; 90: 644-8
4. Hale WE, Perkins LL, May FE, et al. Symptom prevalence in the elderly: an evaluation of age, sex, disease, and medication use. J Am Geriatr Soc 1986 May; 34 (5): 333-40
5. van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21 (2): 179-83
6. Rembratt Å. Nocturia in the elderly: aspects on epidemiology, pathogenesis and antidiuretic treatment [doctoral thesis]. Lund: Department of Clinical and Experimental Pharmacology, Lund University, 2003
7. Barker JC, Mitteness LS. Nocturia in the elderly. Gerontologist 1988 Feb; 28 (1): 99-104
8. Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992 Dec; 40 (12): 1217-20
9. Asplund R. Mortality in the elderly in relation to nocturnal micturition. BJU Int 1999; 84: 297-301
10. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis: a double-blind, crossover trial. Arch Neurol 1996 Dec; 53 (12): 1270-5
11. Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalance of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003; 92: 948-54
12. van Dijk L, Kooij DG, Schellevis FG, et al. Nocturia: impact on quality of life in a Dutch adult population. BJU Int 2004 May; 93 (7): 1001-7
13. Kobelt G, Borgström F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003; 91: 190-5
14. Asplund R, Henriksson S, Johansson S, et al. Nocturia and depression. BJU Int 2004; 93: 1253-6
15. Kallas HE, Chintanadilok J, Maruenda J, et al. Treatment of nocturia in the elderly. Drugs Aging 1999 Dec; 15 (6): 429-37
16. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003 Oct; 189(4): 1106-13
17. George CL, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metabol 1975; 41 (2): 332-8
18. Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983 Sep; 46 (9): 854-5
19. Vilhardt H. Basic pharmacology of desmopressin: a review. Drug Invest 1990; 2 Suppl. 5: 2-8
20. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985 Aug; 103 (2): 228-39
21. Ferring Inc. First and only treatment approved for nocturia: under-reported condition focus of first-ever medical symposia [media release]. 2003
22. Robinson AG. DDAVP in the treatment of central diabetes insipidus. N Engl J Med 1976 Mar 4; 294 (10): 507-11
23. Nadvornikova H, Schuck O, Cort JH. A standardized desmopressin test of renal concentrating ability. Clin Nephrol 1980 Sep; 14 (3): 142-7
24. Ferring AB. Desmopressin (Minirin®, DDAVP®): focus on urological indications. Chester: Adis International Ltd, 1998
25. Butlen D, Guillon G, Rajerison RM, et al. Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormone binding, and antidiuretic actions: effects of highly potent analogues and competitive inhibitors. Mol Pharmacol 1978; 14: 1006-17
26. Brink HS, Derkx FHM, Boomsma F, et al. Effects of DDAVP on renal hemodynamics and renin secretion in subjects with essential hypertension. Clin Nephrol 1994 Aug; 42 (2): 95-101
27. Medina P, Segarra G, Vila JM, et al. V2-receptor-mediated relaxation of human renal arteries in response to desmopressin. Am J Hypertens 1999 Feb; 12 (2 Pt 1): 188-93
28. Mechaly I, Laurent F, Portet K, et al. Vasopressin V2 (SR121463A) and Via (SR49,059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol 1999 Nov 3; 383: 287-90
29. Seif SM, Zenser TV, Ciarochi FF, et al. DDAVP (1-desamino-8-D-arginine- vasopressin) treatment of central diabetes insipidus - mechanism of prolonged antidiuresis. J Clin Endocrinol Metab 1978; 46 (3): 381-8
30. Eller N, Kollenz CJ, Bauer P, et al. The duration of antidiuretic response of two desmopressin nasal sprays. Int J Clin Pharmacol Ther 1998 Sep; 36 (9): 494-500
31. Vilhardt H, Bie P. Antidiuretic effect of perorally administered DDAVP in hydrated humans. Acta Endocrinol (Copenh) 1984; 105: 474-6
32. Fjellestad-Paulsen A, Hogland P, Lundin S, et al. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993 Feb; 38: 177-82
33. Callréus T, Lundahl J, Höglund P, et al. Changes in gastrointestinal motility influence the absorption of desmopressin. Eur J Clin Pharmacol 1999 Jun; 55 (4): 305-9
34. Vilhardt H, Lundin S, Falch J. Plasma kinetics of DDAVP in man. Acta Pharmacol Toxicol (Copenh) 1986; 58: 379-81
35. Vilhardt H, Lundin S. Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen Pharmac 1986; 17 (4): 481-3
36. Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998 Feb; 48: 235-41
37. Williams TDM, Dunger DB, Lyon CC, et al. Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin: 1. Studies in adults and children. J Clin Endocrinol Metab 1986; 63 (1): 129-32
38. Callréus T, Höglund P. Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. Pharmacol Toxicol 1998 Dec; 83 (6): 259-62
39. Ferring Pharmaceuticals A/S. Minirin tablets (desmopressin acetate). Data sheet: information for health professionals [online]. Available from URL: www.medsafe.govt.nz/Profs/Datasheet/m/Minirintab.htm [Accessed 2004 Apr 27]
40. D'Agay-Abensour L, Fjellestad-Paulsen A, Hoglund P, et al. Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. Eur J Clin Pharmacol 1993; 44 (5): 473-6
41. Robertson GL, Mahr EA, Athar S, et al. Development and clinical application of a new method for radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973 Sep; 52: 2340-52
42. Beardwell CG, Geelen G, Palmer H, et al. Radioimmunoassay of plasma vasopressin in physiological and pathological states in man. J Endocrinol 1975; 67: 189-202
43. Agersø H, Larsen LS, Riis A, et al. Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol 2004; 58 (4): 352-8
44. Edwards CRW, Kitau MJ, Chard T, et al. Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. Br Med J 1973 Aug 18; 3: 375-8
45. Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002 Jun; 89 (9): 855-62
46. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004 Sep; 172 (3): 1021-5
47. Eckford SD, Swami KS, Jackson SR, et al. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994 Dec; 74 (6): 733-5
48. Jackson S, Donovan J, Brookes S, et al. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol 1996; 77: 805-12
49. Donovan JL, Abrams P, Peters TJ, et al. The ICS-'BPH' study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 1996; 77: 554-62
50. Kirkland JL, Lye M, Levy DW, et al. Patterns of urine flow and electrolyte excretion in healthy elderly people. Br Med J 1983 Dec 3; 287: 1665-7
51. Abrams P, Mattiasson A, Lose GR, et al. The role of desmopressin in the treatment of adult nocturia. BJU Int 2002 Dec; 90 Suppl. 3: 32-6
52. Ferring Pharmaceuticals Ltd. Desmospray, desmopressin nasal spray. Summary of product characteristics [online]. Available from URL: www.emc.medicines.org.uk [Accessed 2004 Apr 30]
53. Ferring Pharmaceuticals Ltd. DDAVP/desmopressin intranasal solution. Summary of product characteristics [online]. Available from URL: www.emc.medicines.org.uk [Accessed 2004 Apr 30]
54. Williford SL, Bernstein SA. Intranasal desmopressin-induced hyponatremia. Pharmacotherapy 1996 Jan-Feb; 16 (1): 66-74
55. Robson WLM. Water intoxication in patients treated with desmopressin. Pharmacotherapy Sep-Oct 1996; 16: 969-70
56. Williford SL. Water intoxication in patients treated with desmopressin: author's reply. Pharmacotherapy Sep-Oct 1996; 16: 970